You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯邦制藥(03933.HK):阿莫西林克拉維酸鉀片通過仿製藥質量和療效一致性評價
格隆匯 04-24 17:36

格隆匯4月24日丨聯邦制藥(03933.HK)公佈,公司全資附屬公司珠海聯邦制藥股份有限公司中山分公司申報的阿莫西林克拉維酸鉀片(規格:0.375g)經中國國家藥品監督管理局審批,通過仿製藥質量和療效一致性評價。

阿莫西林克拉維酸鉀片是一種青黴素類廣譜抗生素,臨牀常用於治療由產β-內醯胺酶的細菌引起的感染,如呼吸道感染、皮膚及軟組織感染、泌尿系統感染等細菌性感染的治療。其療效明確,安全可靠,是臨牀基礎用藥中廣泛應用的抗菌藥品。現時,阿莫西林克拉維酸鉀為國家基藥目錄(2018年版)及國家醫保目錄(2022年版)甲類藥品。

本次獲批將進一步提升集團產品的品牌價值,提升市場競爭力。未來,公司將持續致力於新產品研發及推進一致性評價,預期將為本公司及其股東創造更大收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account